Retrospective hospital based surveillance of intussusception in children in a sentinel paediatric hospital: benefits and pitfalls for use in post-marketing surveillance of rotavirus vaccines
- PMID: 22520131
- DOI: 10.1016/j.vaccine.2011.11.015
Retrospective hospital based surveillance of intussusception in children in a sentinel paediatric hospital: benefits and pitfalls for use in post-marketing surveillance of rotavirus vaccines
Abstract
Evaluation of the safety of rotavirus vaccines, particularly with respect to the risk of intussusception, is recommended for countries planning to introduce rotavirus vaccines into the National Immunisation Program. However, as prospective studies are costly, require time to conduct and may be difficult to perform in some settings, retrospective hospital based surveillance at sentinel sites has been suggested as an option for surveillance for intussusception following introduction of rotavirus vaccines.
Objective: To assess the value of retrospective hospital based surveillance to describe clinical and epidemiological features of intussusception in children aged <24 months and to investigate any temporal association between receipt of a rotavirus vaccine and intussusception.
Methods: A retrospective chart review of all patients diagnosed with intussusception at Royal Children's Hospital, Melbourne, Australia over an 8-year period including before and after rotavirus vaccine introduction into the National Immunisation Program, was conducted using patients identified by a medical record database (ICD-10-CM 56.1). Patient profile, clinical presentation, treatment and outcome were analysed along with records of immunisation status obtained using the Australian Childhood Immunisation Register.
Results: A 9% misclassification rate of discharge diagnosis of intussusception was identified on critical chart review. The incidence rate of intussusception at the Royal Children's Hospital over the study period was 1.91 per 10,000 infants <24 months (95% CI 1.65-2.20). Intestinal resection was required in 6.5% of infants (95% CI 3.6%, 11.0%). Intussusception occurred within 30 days after vaccination in 2 of 27 patients who had received at least 1 dose of a rotavirus vaccine.
Conclusions: Valuable data on the incidence, clinical presentation and treatment outcomes of intussusception can be obtained from data retrieved from hospital medical records in a sentinel paediatric hospital using standardised methodology. However, there are methodological limitations and the quality of the data is highly dependent on the accuracy and completeness of the patient information recorded, the system of coding and record retrieval.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.Vaccine. 2012 Apr 27;30 Suppl 1:A61-70. doi: 10.1016/j.vaccine.2011.09.026. Vaccine. 2012. PMID: 22520138 Clinical Trial.
-
Changing epidemiology of intussusception in Australia.J Paediatr Child Health. 2005 Sep-Oct;41(9-10):475-8. doi: 10.1111/j.1440-1754.2005.00686.x. J Paediatr Child Health. 2005. PMID: 16150062
-
Intussusception-associated hospitalization among Venezuelan infants during 1998 through 2001: anticipating rotavirus vaccines.Pediatr Infect Dis J. 2003 Mar;22(3):234-9. doi: 10.1097/01.inf.0000055064.76457.f3. Pediatr Infect Dis J. 2003. PMID: 12634584
-
Rotavirus vaccination in Brazil: effectiveness and health impact seven years post-introduction.Expert Rev Vaccines. 2014 Jan;13(1):43-57. doi: 10.1586/14760584.2014.861746. Epub 2013 Dec 4. Expert Rev Vaccines. 2014. PMID: 24308577 Review.
-
Rotavirus vaccines and intussusception risk.Curr Opin Gastroenterol. 2005 Jan;21(1):20-5. Curr Opin Gastroenterol. 2005. PMID: 15687880 Review.
Cited by
-
Childhood intussusception: a literature review.PLoS One. 2013 Jul 22;8(7):e68482. doi: 10.1371/journal.pone.0068482. Print 2013. PLoS One. 2013. PMID: 23894308 Free PMC article. Review.
-
[A rare case of suppurative mesenteric adenitis associated with intussusception in a child: a clinical case].Pan Afr Med J. 2016 Mar 31;23:148. doi: 10.11604/pamj.2016.23.148.8590. eCollection 2016. Pan Afr Med J. 2016. PMID: 27279973 Free PMC article. French.
-
Countering vaccine hesitancy through immunization information systems, a narrative review.Hum Vaccin Immunother. 2019;15(11):2508-2526. doi: 10.1080/21645515.2019.1599675. Epub 2019 Jun 21. Hum Vaccin Immunother. 2019. PMID: 30932725 Free PMC article. Review.
-
Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries.Hum Vaccin Immunother. 2021 Jul 3;17(7):2298-2310. doi: 10.1080/21645515.2021.1885279. Epub 2021 Apr 16. Hum Vaccin Immunother. 2021. PMID: 33861183 Free PMC article.
-
Effect of Formulation Variables on the Stability of a Live, Rotavirus (RV3-BB) Vaccine Candidate using in vitro Gastric Digestion Models to Mimic Oral Delivery.J Pharm Sci. 2021 Feb;110(2):760-770. doi: 10.1016/j.xphs.2020.09.047. Epub 2020 Oct 7. J Pharm Sci. 2021. PMID: 33035539 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical